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1. Introduction 
Replenishing the depleted striatal dopamine stores with its immediate precursor, L-3,4-
dihydroxyphenylalanine (L-DOPA), to mimic dopamine-mediated neurotransmission still 
represents the gold standard for treating Parkinson’s disease (PD). This pharmacological 
therapy offers immediate and effective symptomatic relief, especially at the early stages of 
the disease; it has, however, no influence on underlying neurodegenerative processes (Dass 
et al., 2006) that continue to evolve with time and are paralleled by a gradual loss of drug 
efficacy. As the disease progresses, steady adaptation, mostly continuous increase, of 
dopaminergic drug dosage is necessary, thereby favoring the emergence of considerable 
side effects, such as dyskinesia and psychiatric disturbances. The development of new 
treatments, or combination of treatments, able to relief motor symptoms and also delay or 
even halt the loss of dopaminergic neurons, has been and remains a fundamental issue for 
the development of innovative clinical strategies in PD. Transplantation of dopamine-
secreting cells directly providing dopamine in the striatum, in particular, has been 
considered an adequate substitute to pharmacotherapy. However, although efficacy of this 
approach has now been asserted in numerous pre-clinical studies utilizing animal models of 
PD, positive outcomes in clinical trials involving PD patients have been very variable and 
rather modest, and have been plagued by graft-induced dyskinesias. New sources for cell 
replacement and particularly stem cells (including induced patient-derived cells) may now 
provide advantages for future clinical therapies (Wakeman et al., 2011). 
This chapter will briefly introduce rodent and nonhuman primate PD-like models 
commonly used in pre-clinical studies, which represent a fundamental platform for the pre-
clinical evaluation of innovative interventions. We will then evidence the progresses 
accomplished since the first intracerebral transplantation of fetal neural tissue in PD patients 
describing the subsequent novel discoveries for the application of stem cell to pre-clinical 
PD models, and give an overview of ongoing cell-based therapeutic strategies.  Thereafter, 
multiple issues connected to stem transplantation to efficiently contrast adverse effects of 
increased age will be reviewed including decrease of apoptosis related to tissue 
degeneration, requirement of correct graft integration in the host vascular and neural 
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circuits, reduction of diffuse inflammatory response/oxidative stress and correct release of 
key growth factors. In addition we will discuss the emergence of novel biotechnologies that 
will, most likely, help unravel the complex interrelationship between transplanted stem cells 
and the host environment and will favor the development of novel therapeutic procedures 
readily applicable in PD patients. 
2. Animal models: A necessary pre-clinical tool for the development of 
innovative cellular therapy in PD 
Animal models represent a fundamental step in the attempt to elucidate gene-environment 
interactions and to define pathogenic mechanisms involved in the aetiology and progression 
of the neurodegenerative diseases. Most of the current knowledge on pathophysiology of 
PD originates from studies conducted on animal models of the disease, since animals and 
humans share several anatomical features (as shown in Figure 1). In addition, they represent 
the first essential pre-clinical platform for the evaluation of any targeted therapeutic 
intervention. Notably, subsequent clinical trials in small human cohorts remain essential for 
the development of efficient therapies able also to alleviate disability related non-motor 
symptoms (Meissner et al., 2011) which are currently underestimated in animal models  




Fig. 1. Anatomical comparison between mouse and human brains 
The comparison between rodent (A) and human brain (B) enlightens their anatomical 
similarities and physiology. The connections between striatum, SNc, and cerebral cortex in 
the human brain are indicated by dotted black lines and may correlate the simultaneous 
degeneration of these areas during disease onset and progression.  Moreover, dopaminergic 
innervations of the striatum/SVZ (black dotted lines) could also explain reduction of adult 
brain neurogenesis both in PD patients and animal models. 
PD models have been classically based on the administration of neurotoxins able to replicate 
some of the pathological and phenotypic features of the human disease both in rodents and 
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primates. Toxins can be given systemically or intra-cerebrally, depending on the type of 
toxin used and animal specie involved, and mimic the selective degeneration of nigrostriatal 
neurons characteristic of the human disorder.  
The classical systemic model is based on the injection of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a toxin that selectively affects dopaminergic neurons and first 
recognized in the mid-1980’s as the cause of marked parkinsonism in young drug users of 
Northern California (Langston et al., 1983). MPTP crosses the blood brain barrier and is 
transformed in its active metabolite, 1-methyl-4-phenylpyridinium ion (MPP+) that is then 
actively taken up by dopaminergic neurons of the substantia nigra pars compacta (SNc). 
Systemic administration of MPTP to nonhuman primates induces a parkinsonian phenotype 
closely resembling the human pathology. MPTP-treated monkeys have an excellent anti-
symptomatic response to dopaminergic drug treatment and develop motor complications 
linked to long term L-DOPA therapy (Kim et al., 2009). Concordantly, several 
pharmacological drugs currently applied to treated PD patients (i.e. dopamine agonists, 
amantadine, etc..) have been developed in this MPTP model (Fox et al., 2006). Alternative 
cell replacement strategies using various cell sources have been successfully performed 
indicating the technical feasibility of the model for future studies (Redmond et al., 2010; 
Serra et al., 2008). The large related costs and the difficulty to reliably standardize acute 
toxin administration to replicate most of the underlying mechanisms of a chronic 
progressive disorder form still represent major drawbacks and limit the use of this PD 
model in large scale studies (Fox and Brotchie, 2010). MPTP can also be systemically 
administered to mice but not rat, which are resistant, and several different experimental 
paradigms have been developed and used over time.  
The prototypical intracerebral model is based on the local injection of 6-hydroxydopamine 
(6-OHDA) and was the first PD animal model ever generated (Ungerstedt, 1968). Six-OHDA 
is a hydroxylated analogue of dopamine and, similarly to MPTP, is actively taken up by 
dopaminergic neurons. The neurotoxin can be injected in the SNc, or into the medial 
forebrain bundle (mfb) that conveys efferent fibers from the nigral cell bodies to the striatum 
(as shown in Figure 1) and causes massive and rapid anterograde degeneration of the 
nigrostriatal pathway. This procedure induces large nigral cell loss and striatal dopamine 
depletion (90-100%). The neurotoxin can also be injected into the striatum; in this case rapid 
damage to striatal dopaminergic terminals is observed followed by a progressive loss of SNc 
neurons (50-70% neuronal loss), which are secondarily affected through a “dying back” 
mechanism. This procedure has a slower time course compared to the intra-mfb injection 
and provides a progressive model of nigrostriatal degeneration, more similar to the gradual 
evolution of the neurodegenerative process of human PD. Importantly, injection of 6-OHDA 
is commonly carried out unilaterally, with the contralateral hemisphere serving as control, 
because of the high mortality rate associated with bilateral injection. The rat 6-OHDA model 
is commonly used in neuroprotective studies, both involving administration of novel 
pharmaceutical compounds or cell transplantation because it is i) cost-effective, ii) highly 
reproducible and iii) opened to articulate behavioural analyses (Redmond et al., 2010; Serra 
et al., 2008).  
Numerous transgenic mouse models, that reproduce monogenic mutations observed in 
familiar forms of PD, have also been developed over the years. These models have not been 
discussed in this chapter as they typically display very low degree or even no nigrostriatal 
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3. Neural tissue transplantation 
In 1987, the first clinical trials involving transplantation of human fetal mesencephalic 
tissues or xenotransplantation of fetal pig neural cells in humans were performed with the 
clear scope of replacing dopaminergic neurons lost during PD progression. Since then and 
overall, contradictory results have been observed, even among patient groups treated within 
the same centers (Bjorklund et al., 2003). Along with the observed poor graft survival 
(around 10%; (Hagell and Brundin, 2001), a substantial subset of patients (15-56%) 
developed dyskinesias (Freed et al., 2001; Hagell and Brundin, 2001; Olanow et al., 2003), 
while the presence of Lewy bodies in long-term implants, recently reported, suggests the 
possibility of a host-to-graft disease propagation (Kordower et al., 2008; Li et al., 2008; 
Mendez et al., 2008). Functional improvements, represented by reduction of symptoms 
(30%–40% improvement of the unified Parkinson’s disease rating scale, motor score in the 
drug-free phase) have been clearly observed (Hagell and Brundin, 2001) even in the long 
term (Mendez et al., 2008; Piccini et al., 1999). Positive outcomes were dampened by 
enhanced microglial activation and disruption of blood brain barrier linked to surgical 
procedures (Olanow et al., 2003). Failures were also related to the scarcity, as well as 
heterogeneous composition of the donor tissue itself (Carlsson et al., 2009; Freed et al., 2001). 
Nonetheless, these first trials supported the feasibility of transplantation procedures as an 
alternative therapeutic approach in PD (Brundin et al., 2010; Olanow et al., 2003). Moreover, 
these first trials have enlightened critical parameters mandatory for successful 
tranplantations including: a) purity of cell preparation; b) correct localization of the graft  in 
the host brain c) preference for reduced age of donor/host cells (whenever possible), d) 
limited extension of brain injury at the time of transplantation (early pathological phases), 
and e) appropriate time of grafting (in relation to disease onset) to maximize survival of 
endogenous dopaminergic neurons (Lindvall and Kokaia, 2009). Altogether, these 
observations have encouraged the search for alternative cell sources that need to be efficient, 
safe, and ethically acceptable (additional details on this debated/controversial topic can be 
found in (Kimmelman et al., 2009)). 
4. Stem cell therapy 
The scientific progresses in biological and cellular technologies have allowed a better 
conception of the mechanisms involved in cell development, and in particular of 
factors/conditions ruling Stem Cells (SCs) proliferation and differentiation. Essentially, SCs 
are undifferentiated multipotent cells capable of both self-renewal and generation of several 
differentiated functional cell types to preserve tissue homeostasis throughout the entire life 
span of an organism. Multiple properties of SCs, including their the ability to potentially 
generate an unlimited number of dopaminergic neurons under physiological conditions, 
make them attractive candidates for regenerative therapy (Dass et al., 2006). 
Therefore, SCs have been increasingly recognized as a valuable replacement and/or 
supporting tool for PD wherein a well-characterized cell type is mainly affected. Cell 
therapy may be performed using either autologous (ideal from an immunologic perspective) 
or allogeneic tissue-specific differentiated cells. Transplantation of healthy SCs that have 
been collected, expanded and eventually pre-differentiated in vitro have been originally 
proposed as a feasible appealing neural-replacement strategy. To date, several fetal and 
adult SC lineages have been directly differentiated into multiple cellular types, including 
neural cells and dopaminergic phenotypes. These naïve SCs, or their induced neuronal 
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progeny, have been successfully transplanted in animal models of PD granting significant 
behavioral improvements. Ideally, however, new therapies should not only aim at 
replenishing the depleted dopamine store, but should also allow rescue of neuronal 
terminals and soma both in striatum and SNc.  
Innovative therapeutic strategy should also take advantage and enhance the plastic property 
of the adult Central Nervous System (CNS) to regenerate affected brain areas through the 
activation of endogenous neurogenesis following cell transplantation. To reach these targets, 
other known intrinsic properties of SCs have already been exploited. Indeed, the potential of 
SCs to restore injured tissues is not only related to their direct differentiation but also to 
their capacity to produce and release trophic factors that may in turn inhibit apoptosis, 
promote angiogenesis and even direct stimulation of host regeneration (Lindvall and 
Kokaia, 2009; Lindvall and Kokaia, 2010). Neuroprotection can also be enhanced by 
transplanting SCs engineered to express either tyrosine hydroxylase (TH), the rate-limiting 
enzyme of dopamine synthesis, or neurotrophic factors, such as glial cell-line derived 
neurotrophic factor (GDNF), the most potent survival factor for degenerating dopaminergic 
neurons. Grafting of engineered SCs in this case provides a substantial reservoir allowing 
the unlimited supply of the required substance without the requirement of invasive 
injection pumps, as detailed below. Several SC types have already been transplanted in PD 
animal models yielding interesting but variable results (Wakeman et al., 2011). 
SCs can be efficiently derived from early stage embryos (pluripotent SCs with unlimited 
potential to differentiate) or from committed resident tissues (multipotent SCs with 
restricted potential to differentiate). Interestingly almost all organs arising from 
endodermal, mesodermal and ectodermal germ layers can originate both fetal and adult SCs 
(i.e. amniotic/cord blood and tissue derived SCs). Regardless of their origin SCs could 
physiologically repair damaged tissues after intense injuries also promoting angiogenesis 
and neurogenesis processes, essential for CNS development and regeneration (Lindvall and 
Kokaia, 2010).  
4.1 Embryonic stem cells 
Embryonic Stem cells (ES) are derived from the inner cell mass of pre-implantation embryos 
and are a source of pluripotent cells, as they are able to differentiate into all adult cell types. 
Once established, the pluripotent ES cells can be maintained under defined culture 
conditions, but can also be induced to terminally differentiate into a specific lineage 
(Bibikova et al., 2008). ES cells may potentially give rise to an infinite number of 
dopaminergic neurons that may be subsequently transplanted in depleted brain areas either 
in animal models of PD or even in patients (Lindvall and Kokaia, 2009). A particular 
emphasis has been posted on the validation of reliable methods for differentiation of ES cells 
towards midbrain dopaminergic neurons with a high survival index following 
transplantation (Hwang et al., 2010). Several protocols, characterized by presence of 
different feeder cell layers (i.e. bone marrow stromal cells, (Perrier et al., 2004) or astrocytes 
(Roy et al., 2006)) coupled to morphogen/growth factor exposition, have been developed. 
Transplantation of these in vitro-differentiated cells has produced variable results and often 
gave rise to tissue overgrowth with formation of neuroepithelial tumors, probably linked to 
the presence of residual immature cells in the original grafts. To overcome uncontrolled 
proliferation within transplants, cell-sorting protocols have been applied to specifically 
isolate pure populations of ES-derived dopaminergic neurons. These procedures, however, 
selectively impaired neuron survival indicating that fundamental factors were lost in the 
negative fraction (Friling et al., 2009).  
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Recently, epigenetic manipulation to force dopaminergic gene expression has been also 
exploited (Andersson et al., 2006). Following transplantation in parkinsonian rats, these 
differentiated cells integrated in the brain of the animals and significantly improved PD-
related behavioral stereotypies (Yang et al., 2010). Application of this methodology to 
clinical practice, however, remains unrealistic until well-standardized, tumor-free samples 
will be available. Additional protocols for induction of dopaminergic phenotypes in ES cells 
have been recently developed (Chambers et al., 2009; Cooper et al., 2010), but functional 
efficacy of these cells has not been tested in PD animal models yet.  Moreover, their use is 
still limited by our scarce knowledge of the development and specification of midbrain 
dopaminergic neurons (Pruszak and Isacson, 2009). Altogether, all experimental studies 
performed so far, demonstrate that ES-derived dopaminergic neurons are still unable to 
efficiently survive in and innervate lesioned brain areas in animal models of PD without 
inducing the formation of tumors (Arenas, 2010). In addition, ES cells frequently carry 
aberrant chromosome content in relation to growth advantage (Meisner and Johnson, 2008). 
Finally, the therapeutic application of ES cells will necessarily require both animal cell- and 
serum-free conditions (Klimanskaya et al., 2005), still substantially limiting their 
standardized application in clinic (Gruen and Grabel, 2006). 
4.2 Induced pluripotent SCs  
Recently, induced Pluripotent SCs (iPS) have been derived from primary fibroblast cultures 
obtained from cutaneous biopsies of patients affected by neurodegenerative diseases (Kriks 
and Studer, 2009; Lindvall and Kokaia, 2009). This complex reprogramming sequence was 
performed by exogenous expression of specific transcription factors that allowed a cellular 
switch from an epigenome of reduced potency to one of pluripotency (Kiskinis and Eggan, 
2010). The resulting iPS cells could then be differentiated into autologous, patient-specific 
non-mitotic cells, such dopaminergic neurons and glial cells, normally present only in the 
CNS, and generally only available post-mortem.   
iPS cells present several advantages when compare to ES cells: 1) their possible autologous 
derivation (Park et al., 2008b), 2) the consequent lack of mandatory immunosuppressant 
therapy following transplantation, and 3) the absence of ethical concerns related to embryo 
disruption (Arenas, 2010). These derived and/or differentiated cells can be used as donor 
cells in transplantation paradigms and represent a valuable tool to dissect intrinsic 
pathological mechanisms or test new pharmacological approaches in samples not readily 
available from live patients (Abeliovich and Doege, 2009; Gunaseeli et al., 2011; Xu et al., 
2010a). However, the use of oncogenes or retrovirus in the current iPS cell establishment 
protocol raises considerable safety concerns (Pasi et al., 2011). Indeed, iPS progenies show 
high propensity to form teratomas considerably restricting their potential use in cell therapy 
(Miura et al., 2009). Heterogeneity of iPS cell composition with variable levels of transgene 
expression overtime suggests a prudent approach for iPS application to clinical trials 
(Kiskinis and Eggan, 2010). Recently, alternative protocols that allow direct fibroblast 
reprogramming towards neurons without generation of pluripotent cells have been 
developed (Vierbuchen et al., 2010). An additional notable potential risk of autologous 
therapeutic reprogramming is linked to the possibility that unknown genetic factors, 
involved in the patient’s disease, could also potentially lead to disease-related alterations of 
the transplanted cells in the long term (Hwang et al., 2010). Transplantation of committed 
neural cells selected from differentiated PD patient-derived iPS cells has been tested in a 
lesional rodent model of PD with some overall beneficial effects. Transplanted cells 
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integrated into the striatum of parkinsonian rats and improved behavioral deficits for up to 
8 weeks, although no noticeable dopaminergic innervation from grafted cells to the 
surrounding striatum was observed (Wernig et al., 2008). Recently, Hargus et al, showed 
that iPS–derived dopaminergic neurons can be implanted and survive, without signs of 
neurodegeneration or tumor formation, both in healthy and 6-OHDA lesioned rats (Hargus 
et al., 2010). Although the grafted cells sent proper projections to close and remote target 
areas, acquisition of the appropriate regional identity is still argued. A significant behavioral 
improvement related to high survival of the transplanted dopaminergic neurons was also 
reported in simple, but not in complex motor functions, that rely on functional connections 
between grafted and host cells. Therefore, whether these preliminary results can be 
successfully translated into human clinical studies still awaits more experimental data 
(Hanna et al., 2010). Additional long-term studies will be necessary to recreate the correct 
pathophysiological conditions before validation of this model as an alternative cell-based 
therapy in PD (Kiskinis and Eggan, 2010). It has been hypothesized that an effective 
therapeutic effect following transplantation requires the survival of at least 105 
electrophysiologically active dopaminergic cells, appropriately contacting and 
reinnnervating striatum, without tumor formation (Arenas, 2010). Nevertheless, iPS cells 
could still be exploited for drug screening or as disease model to unravel pathological 
cascades in PD (Xu et al., 2010a). An important draw back in the clinical application of iPS 
cells also resides in the elevated production costs of personalized iPS. The establishment of 
centralized iPS cell bank(s) has been proposed to insure that fibroblast-derived 
dopaminergic neurons for transplantation are obtained following the Good Manufacturing 
Practice (GMP) guidelines for clinical trial materials.  
4.3 Patient-derived Neural SCs 
An innovative cellular approach is based on patient-derived neural stem cells (NSC) 
obtained from biopsies of their olfactory mucosa biopsies. This procedure allows the 
derivation of large quantities of NSC that can be grown in vitro as floating differentiable 
neurospheres. The cells bear significant pathological, disease-specific alterations in gene and 
protein expression, as well as cell function, such as dysregulated mitochondrial function, 
oxidative stress and xenobiotic metabolism (Matigian et al., 2010). Direct exploitation of 
these patient-derived neural cells will help obtain new insights in specific candidate genes 
and cell pathways for future studies of brain disease. These SCs could partially overcome 
the lack of appropriate animal models, faithfully recapitulating all of the clinical and 
pathological phenotypes of the disease, to study the mechanisms underlying PD as well as 
to develop translational drug development (Schule et al., 2009). In addition, these cells have 
a considerable advantage over ES and iPS cells, as they do not require reprogramming, and 
represent an important tool, with a considerable translational impact to all complex 
diseases. Moreover, biopsies easily obtained from neural tissues could supply new 
biomarkers for monitoring disease progression in PD patients. Development of such 
biomarkers represents a necessary step for the accomplishment essential for quality research 
and clinical trials (Lebouvier Thibaud et al., 2010). Derivation of patient NSC encompasses 
all the specific gene-environment interactions which appear fundamental along ageing 
process in sporadic neurological as well as psychiatric disorders (Matigian et al., 2010). 
Patient derived SCs are particularly intriguing for their potential in cell therapy and 
regenerative medicine: they may provide novel insights for the development of therapeutic 
strategies, aiming to contrast the neurodegenerative processes of PD. The discovery of the 
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specific molecules involved in these biological events could also shed light on new 
pharmacological disease-modifying treatments and novel potential targets, readily 
applicable to patients (Schule et al., 2009). 
Anyway, a cautionary approach is required, since this invasive methodology still requires 
development of standardized, validated protocols able to reach a structure (olfactory 
mucosa) not accessible to routine biopsies (Parkkinen et al., 2009)].  
4.4 Multipotent adult stem cells 
Multipotent SCs have been identified within specific niches in most adult tissues including 
bone marrow, muscle, brain, heart and liver. Adult SCs that comprise fetal, amniotic, 
umbilical cord blood, placental, as well as tissue derived SCs (i.e. hematopoietic, neural, 
mesenchymal, skin SCs) are less abundant and proliferative, and possess limited potential to 
differentiate compared to ES cells. A key added value of adult SCs, however, is their 
potential use in autologous therapies, in which cells can be harvested and used within the 
same patient, thus avoiding the ethical concerns and risks linked to ES cells (Fricker-Gates 
and Gates, 2010). The ideal procedure involves isolation of SCs from tissues and their 
preservation in standardized stocks at centralized unit banks for long term storage and 
subsequent transplantation into patients upon request (Arenas, 2010) (see Figure 2). In this 
section we will summarize the actual state of the art and deadlocks regarding three main SC 
lineages: hematopoietic (HSC), mesenchymal (MSC) and neural (NSC).  
Bone marrow resident HSC and MSC constitute two important cell sources for pre-clinical 
transplantation. HSC can be easily derived from autologous/allogeneic bone marrow or 
peripheral blood, and are routinely used in transplantation procedures for the treatment of 
several immuno-deficient/autoimmune diseases, as well as hematopoietic disorders, to 
reconstitute peripheral cell lineages (i.e. leukocytes, erythrocytes, etc). Recently, 
transplantation of HSC, engineered to release TH, has been reported to produce significant 
therapeutic effects in PD rats (Zhang et al., 2008). 
A large body of data on the application of MSC in cell therapy can be found in literature; 
MSC are non-hematopoietic, multipotent cells which arise from the stromal structures of the 
bone marrow and are preserved in adults (Picinich et al., 2007). MSC can generate mature 
endothelial cells and several mesenchymal cell lineages including osteoblasts, chondrocytes, 
adipocytes and myoblasts (Liu et al., 2009). Several publications report efficient and multi-
disciplinary protocols for their differentiation, in vitro, towards dopaminergic neurons 
(Heinrich et al., 2009; Kitada and Dezawa, 2009) even including the use of lentiviral vectors 
to induce TH expression (Barzilay et al., 2009). Positive outcomes in acute hypoxic-ischemic 
damages have been obtained utilizing MSC isolated from several stem sources, such as 
human placenta and amniotic fluid, either naïve (Cipriani et al., 2007) or following neural 
differentiation (Park et al., 2011). Positive results, such as stability and physiology of the 
correct phenotype in vitro (Thomas et al., 2011) and in vivo after transplantation of MSC in 
animal models of PD (Shetty et al., 2009), as well as in PD patients (Venkataramana et al., 
2010) have been reported. The long-term fate of grafted cells is still, however, matter of 
debate (Schwarz and Storch, 2010; Schwarz and Schwarz, 2011) and application of cell 
therapy to a chronic degenerative disease like PD appears rather complex. Successful 
outcomes of transplantation can be influenced by multiple factors largely dependent on the 
source and type of SCs adopted. For example, it has been reported that neural 
differentiation of MSC is required before intrastriatal transplantation in PD rats to observe a 
graft-dependent improvement of motor deficits (Levy et al., 2008). Transplantation of naïve 
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human umbilical vein-derived dopaminergic-like cell in a rat model of PD did not improve 
motor dysfunction, and required administration of a neurotrophin, nerve growth factor, to 
induce substantial recovery (Li et al., 2010a). Lineage negative cells from umbilical cord 
blood efficiently gave rise to neuronal cells and oligodendrocytes in vitro (Chua et al., 2009) 
while lineage specific (cKit+) amniotic-derived SCs fail to acquire a dopaminergic 
phenotype after epigenetic stimuli both in vitro and in an animal model of PD (Donaldson et 
al., 2009). Concordantly, upon neuronal induction bone marrow-derived MSC down-
regulate markers of other lineages, but fail to differentiate into functional neurons (Thomas 
et al., 2011). The functional positive effects exerted by transplanted MSC in PD animal 
models, are still controversial on the basis of technical criticisms, strength of trial design or 
inconsistent experimental approaches (Meyer et al., 2010). MSC have a significant protective 
effect against dopaminergic cell loss both in vitro and in vivo (Park et al., 2008a), but whether 
this results from true dopaminergic neuron replacement and how the cells actually induced 
functional improvement are still far from being clarified (White, 2011). Thus, before MSC 
can be considered a reliable source for clinical replacement of dopaminergic cells, their 
ability to transdifferentiate terminally towards a neuronal lineage needs to be resolved and 
their mechanism of action following transplantation needs to be elucidated (Schwarz and 
Storch, 2010).  
Another promising source of SC is represented by NSC, that can be derived from various 
source including the subventricular zone (SVZ), ES, umbilical cord blood, MSC, fetal brain 
as well as spinal cord, and grown in suspension as floating clusters (neurospheres) (Meyer 
et al., 2010). NSC can restore functions lost during ageing, and both migrate towards and 
repair neurological damages, exerting positive influence on the surrounding cells, including 
dysfunctional neurons (Ourednik et al., 2002). Autologous transplantation of in vitro-
expanded cortical and subcortical tissue samples, obtained from a PD patient during a 
neurosurgical procedure, produced long lasting motor improvements (Lévesque et al., 
2009). Interestingly, fetal and adult NSC possess comparable intrinsic therapeutic potential 
in terms of cell survival, integration and functional outcomes in a rat model of PD (Muraoka 
et al., 2008). However, albeit feasible, harvesting samples from patient remains an invasive 
procedure and is difficult to translate into a routine therapy. NSC do not give rise to 
dopaminergic neurons under physiological conditions, but several protocols have been 
optimized for their forced differentiation towards this lineage. Mimicking the procedures 
for dopaminergic differentiation from ES cells, a group has reported the differentiation of 
immature NSC into forebrain, but not midbrain (area A9), dopaminergic cells (Papanikolaou 
et al., 2008), while forced expression of Nurr1, a transcriptional factor specific for midbrain 
dopamine neuron development, induced dopaminergic neuron phenotype in NSC isolated 
both from SVZ and the white matter (Shim et al., 2007). The appearance of specific neuronal 
subtypes is not solely a direct consequence of external cues or the expression of 
neurotrophins but likely depends on the integrated temporal sequence of multiple factors 
that finally results in the correct neuronal phenotype. Regionalization and specification of 
the midbrain territory rely on a defined pattern of transcription factor expression and 
secretion of soluble molecules within the neuroectoderm in physiological conditions. This 
pattern is a composite process difficult to correctly recapitulate in vitro and has been only 
partially unraveled (Fricker-Gates and Gates, 2010). Interestingly, transplantation of NSC 
derived from MSC, using a complex protocol based on TH transfection and culture in media 
for differentiation, in 6-OHDA lesioned rats has been recently reported. Cell grafting 
induced significant behavioral improvements that were associated with partial preservation 
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of dopamine content (Zou et al., 2010). A similar approach was applied to MPTP-lesioned 
parkinsonian rhesus monkeys; transplantation of TH- transfected bone marrow cells in the 
caudate nucleus and SNc improved both PD-related alterations in glucose metabolism and 
dopamine transport with an overall recovery of behavioral symptoms (Xu et al., 2010b). 
Similarly, allogeneic NSC modified to stably express and release the neurotrophic factor 
Neurotrophin-3 (NT-3), displayed enhanced dopaminergic neuron differentiation as well as 
migration distance, and induced the reinnervation in the neural circuitry coupled to 
functional recovery upon transplantation in 6-OHDA-treated rats (Gu et al., 2009). Recently, 
Murrell and colleagues proposed that dopaminergic neurons may be generated directly 
from adult olfactory SC of PD patients, similarly to Matigian et al (Matigian et al., 2010): in 
this paper the authors further demonstrated that differentiation of neural progenitor cells in 
dopaminergic-like neurons was able to correct behavioral asymmetry in the rat model of PD 
(Murrell et al., 2008). 
Albeit these overall positive data, additional long term trials on the safety, efficacy, as well 
as further understanding of the biological mechanisms activated by graft procedures still 
need to be accomplished. So far, real functional integration between ectopically grafted SC-
derived dopaminergic neurons in the denervated striatum has been demonstrated only in 
organotypic cultures of wild type mouse striatum (Tonnesen et al., 2011). Therefore, studies 
aimed at the characterization of the molecular basis of the integration in/differentiation of 
(genetically modified) NSC, and their progeny, within the dopaminergic network deserve 
further extensive development. Finally, the invasive intracerebral procedure required for the 
isolation of NSC as a possible SC source in the treatment of neurodegenerative diseases still 
remains a major draw back for their clinical application.  
It is also important to notice that all the three SC lineages (HSC, MSC and NSC) can be 
obtained from bank-stored umbilical cord blood and amniotic/placenta cells, while only 
HSC and MSC can be easily isolated from autologous peripheral blood, thus amplifying the 
potential SC pool for clinical or experimental settings without ethical concerns (Figure 2). 
5. Stem Cell & Neuroinflammation 
Recent discoveries regarding the role of the immune system in brain damage coupled to the 
development of new technologies to manipulate the immune response make 
immunotherapies an attractive target to treat neurological diseases (Tansey and Goldberg, 
2010). In the past decade, neuroinflammation has emerged as an important substrate for PD 
(Brochard et al., 2009). Several epidemiologic studies have reported an inverse correlation 
between the chronic assumption of non-steroidal anti-inflammatory drugs and the risk of 
developing PD (Chen et al., 2003). Unrestrained widespread neuroinflammation emerges 
during the early phases of the neurodegenerative process both in PD patients and in animal 
models of the disease (Whitton, 2010) and significant evidence demonstrates that 
neuroinflammatory processes participate in PD pathophysiology. Gliosis and lymphocyte 
infiltration associated with production of soluble factors – potentially protective or toxic - 
are consistently reported in parkinsonian animals and PD patients (McGeer et al., 1988; 
McGeer and McGeer, 2004; McGeer and McGeer, 2008)  Most studies in animal models of 
PD have demonstrated that efficient neuroprotective strategies that decrease nigrostriatal 
degeneration also consistently reduce associated neuroinflammatory processes, and vice-
versa, underlying the fundamental link between neuroinflammation and neurodegeneration. 
Recent data have also supported the idea that a reduction in the levels of anti-inflammatory 
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factors itself can further enhance vulnerability of dopaminergic neurons to apoptosis in a 
neurodegenerative environment (Barnum and Tansey, 2010; Lu et al., 2010; Maguire-Zeiss 
and Federoff, 2010). Furthermore, it has been recently suggested that pro-inflammatory 
cytokines exert a negative impact on neuronal differentiation, while anti-inflammatory 
cytokines facilitate neurogenesis (Mathieu et al., 2010) and neuronal migration towards 
appropriate targets (Das and Basu, 2008). These data clearly indicate that pro- and anti-
inflammatory responses must be strictly balanced to prevent the potential detrimental 
effects of prolonged or unregulated inflammation on vulnerable neuronal populations (Lee 
and Park, 2009). It has been shown that outcome of the transplantation of ES-derived TH-
positive cells in an MPTP mouse model of PD is strictly dependent on the concomitant 
administration immunosuppressive treatment (Toriumi et al., 2009) that significantly 
improved survival and integration of grafted SC overtime.  
Noteworthy, inflammation, which has long been considered as thoroughly disastrous for 
brain repair, is now known to produce some positive effects on stem/progenitor cell 
recruitment/survival by growth factor signalling and the secretion of chemoattractant 
cytokines (Cayre et al., 2009; Mathieu et al., 2010). Conversely, inflammatory mediators, 
such as nitric oxide (NO) and reactive oxygen species (ROS), can contribute to 
neurodegeneration by triggering aberrant protein modifications with consequent misfolding 
and loss of function (Vicente Miranda and Outeiro, 2010). Application of MSC, a particular 
SC lineage described above (section 4.4), that knowingly possess significant inherent 
immunomodulatory properties, opens new perspective for cell transplantation in PD. MSC 
can interactively act on their environment through the local/distal release of trophic factors, 
as well as on the activation of immune response by means of cell contact-dependent 
mechanism and modulation of noxious inflammatory components (Lee and Park, 2009). 
MSC were proven to effectively protect dopaminergic neurons from lipopolysaccharide 
(LPS)-induced neurotoxicity, both in vitro and in vivo, via anti-inflammatory mechanisms 
involving the modulation of microglial activation (Kim et al., 2009). Microglia, in turn are 
responsible for the correct phagocytic clearance following injury, thus facilitating the 
reorganization of neuronal circuits and triggering repair (Neumann et al., 2009). Notably, 
aside from immunomodulation, the complex network of biological mechanisms activated by 
MSC transplantation includes their homing to the SNc, substitution of dopaminergic 
neurons, modulation of apoptosis and modification of ubiquitin-proteasome function. 
Concordantly, at the moment, MSC constitute the most attractive and autologous candidate 
disease modifying strategy for PD and other neurodegenerative disorders (Karussis et al., 
2008).  
6. Neurorepair/Neurogenesis 
The nigrostriatal network is highly organized and finely regulated in relation to specific 
functions and circumstances. As a consequence, restoring lost dopaminergic neurons does 
not necessarily coincide with correct reconstruction the pathway (Obeso et al., 2008). Partial 
maintenance of neuron survival and function in the SNc within the neurodegenerative 
environment, following transplantation of SCs could, per se, potentially translate in 
significant therapeutic outcomes. Substantial neuroprotective effects against dopaminergic 
depletion have been observed, for example, after transplantations of naïve, undifferentiated 
SCs such as adult adipose-derived adult stromal cells (McCoy et al., 2008), human NSC 
(Yasuhara et al., 2006) or human MSC (Blandini et al., 2010) in 6-OHDA lesioned rats. 
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Similarly, neuroprotection was evident following grafting of human MSC in an animal 
model of progressive parkinsonism (Park et al., 2010; Park et al., 2008a). In an interesting 
approach, transplantation of genetically engineered NSC, in animal models of brain tumor 
or injury, could served as incessant sources of secreted therapeutic agents (neuroprotective 
or tumoricidal) playing the role of biological minipumps (Chen et al., 2007). This procedure 
could readily be applicable to neurodegenerative diseases, including PD. As already 
described for neuroinflammation, the complex interactions between grafted SCs and 
endogenous surrounding cells can reciprocally influence outcome of transplantation both 
through direct interconnections (adherent junctions) or long distance mediations (release of 
soluble factors) (Boucherie and Hermans, 2009). In Amyotrophic Lateral Sclerosis for 
example, non-neuronal neighboring cells, including astrocytes, can drastically enhance 
neuronal survival (Nagai et al., 2007). Concordantly, in PD, glial cells play a critical role in 
homeostatic mechanisms that promote neuronal survival through release of an array of pro- 
and anti-inflammatory cytokines, anti-oxidants and neurotrophic factors within the 
microenvironment of the brain (L' Episcopo et al., 2010). Interestingly, grafting of MSC 
differentiated towards astrocyte-like phenotypes resulted in relevant improvements of 
motor impairment in 6-OHDA lesioned rats in the absence of dopaminergic differentiation 
(Bahat-Stroomza et al., 2009). Similarly, naïve MSC transplanted in the striatum of 6-OHDA 
lesioned animals acquired a glial-like phenotype and significantly reduced the toxin-
induced neurodegeneration (Blandini et al., 2010).  
Recent innovative approaches also include the use viral vectors to induce selected SC to 
produce/release specific neurotrophins possibly active in repairing/rescuing the 
degenerating nigrostriatal system. New protocols for efficient transduction of MSC allowing 
enhanced delivery of GDNF have been developed. Transplantation of the transduced cells 
in experimental PD resulted in the preservation of striatal TH immunoreactivity around the 
graft (Moloney et al., 2010). Similarly, GDNF- and Brain Derived Neurotrophic Factor 
(BDNF)-secreting MSC transplanted in 6-OHDA lesion rats improved behavioral deficits, 
typically detected in these animals (Sadan et al., 2009). Human neural progenitor cells that 
had been genetically modified to release GDNF, readily survived without tumor formation, 
following the intrastriatal transplantation into the brain of aged monkeys (Behrstock et al., 
2006). A comparative study with non human primate has evidenced that the striato-nigral 
axon-transport is also compromised in advanced PD patient potentially limiting the regular 
retrograde transport of factors towards affected neuronal bodies in the SNc (Bartus et al., 
2011). These therapeutic strategies may, therefore, be applicable mainly to patients at an 
early stage of the disease when part of the nigrostriatal network is still spared and may be 
rescued. Different clinical approaches may be required as disease proceeds with the wide 
loss of dopaminergic neurons (Rascol, 2009).  
Donor cells, to physiologically repair damaged neural circuitry using SC transplantation, 
must be able to survive in sufficient number, to differentiate into the appropriate cell type 
and to adequately support the host brain environment. To optimize functional recovery and 
minimize side effects, grafted SCs should be able to functionally integrate in and be 
regulated by the host brain. Outcome of transplantation may be directly affected by time of 
grafting and cell number (Darsalia et al., 2011). Correlation between cell amount and 
therapeutic effects has, for example, been demonstrated for naive MSC that dose-
dependently and regionally sustained the survival of striatal/nigral dopaminergic terminals 
and enhanced neurogenesis, following intrastriatal transplantation in parkinsonian rats 
(Blandini et al., 2010; Cova et al., 2010). Among the pathogenetic mechanisms involved in 
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PD a role of reduced neurogenesis has been suggested (Geraerts et al., 2007). The SVZ, one 
of the two neurogenic zones region located in the lateral wall of the ventricles that maintains 
the largest pool of proliferating cells in the mature mammalian CNS, receives organized 
projections from the SNc. These efferent projections can influence precursor cell 
proliferation in both adult animal (Baker et al., 2004; O'Keeffe et al., 2009a) and primate 
models (Freundlieb et al., 2006), probably through dopamine-induced release of Epidermal 
Growth Factor in the SVZ (O'Keeffe et al., 2009b). Dopaminergic denervation within SVZ 
causes a reduced rate of neural precursor mitosis and abridged neuronal maturation in the 
long term, a phenomenon common among PD patients (Hoglinger et al., 2004) and toxin-
induced animal models of PD (Aponso et al., 2008; He et al., 2006; He et al., 2008; Winner et 
al., 2009; Winner et al., 2006).  
 
 
Fig. 2. Schematic flow chart for cell therapy in PD 
A clinical approach to PD therapy will require 1) SC isolation (possible from different 
sources) 2) their expansion in vitro 3) direct or delayed transplantation through alternative 
or multiple administration routes. Independently from SC type and injection site, the 
therapeutic outcomes will depend upon donor and host ages, extension of the neuronal 
degeneration and graft size. The possible reparative mechanisms exerted by SC 
transplantation comprise neuronal replacement, neuroprotection of residual dopaminergic 
neurons and stimulation of endogenous neurogenesis, which may variably contribute to 
observed behavioral and physiological improvements. In PD cell therapy all the 
manipulations involving SCs should be conducted following the GMP guidelines in the 
absence of serum or other animal components.    
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Release of growth factor by grafted SC may influence adult neurogenesis and up-regulate 
self renewal and/or differentiation of adult host cells both under physiological and 
pathological conditions. Pre-clinical data suggest that modulation of endogenous 
neurogenesis may represent an alternative ways to slow down neuronal cell loss and 
possibly regenerate affected brain areas by modulation of endogenous neurogenesis 
(Geraerts et al., 2007; Okano et al., 2007). Administration of several growth factors (i.e. 
Transforming Growth Factor-α, BDNF and Fibroblast Growth Factor) in striatum 
enhanced neuronal differentiation within SVZ with overall improvements in murine 
behavior (Chiocco et al., 2007). Moreover, in the SNc pharmacological activation of 
dopamine receptor D3 with a selective agonist -7-hydroxy-N,N-di-n-propyl-
2aminotetralin- induced cell proliferation and maturation towards dopaminergic 
phenotype (Van Kampen and Eckman, 2006), thus suggesting the possible occurrence of 
adult neurogenesis in this region under the pathological conditions in PD (Arias-Carrion 
et al., 2009). Presence of neurogenesis in the SNc suggests that disease progression may 
rely on the loss of dopaminergic neurons as well as on the malfunctioning in their 
turnover. Possible efficacy of orthotopic dopaminergic neurogenesis in PD has been 
questioned for a long time (Hermann and Storch, 2008), but transplantation experiments 
have indicated that several SC types, including neural precursors (Arias-Carrion et al., 
2006; Madhavan et al., 2009) and MSC (Cova et al., 2010), can significantly support 
endogenous neurogenesis during the degenerative process in animal models of PD (Hess 
and Borlongan, 2008). Neurogenesis has been confirmed in SVZ of human brains (Curtis 
et al., 2007), but its physiological role is still uncertain (Zhao et al., 2008). Similarly, the 
existence of an improved neuronal reconstruction in the basal ganglia of the human PD 
brain (Yoshimi et al., 2005) is still a matter of debate. The reasons for decreased 
neurogenesis observed with aging and in pathological states may be related to an intrinsic 
inability to respond to the proliferative stimulation in the neurogenic niche, a reduction in 
the number of proliferative SC number, or the presence of activated microglia and 
neuroinflammation (Russo et al., 2011). Therefore, unraveling the localization as well as 
the degree of neurogenesis rate in human brains, together with the discovery of the 
specific molecules involved in these biological events, could lead to the discovery of new 
pharmacological disease-modifying treatments and novel potential targets, readily 
applicable to PD patients (Lindvall and Kokaia, 2010). Finally, it appears realistic to 
combine the synergistic effects between exogenous and endogenous SC actions to obtain 
cues on potential mechanisms involved in the noxious effects of neurodegeneration in PD 
as possible targets for clinical therapy (see Figure 2) (Madhavan and Collier, 2010). 
7. Stem cell transplantation: Delivery method and timing  
To date different SC types, as well as route of cell administration have shown efficacy in 
animal models. Two main routes have been generally used for SC delivery: intracerebral 
and intravascular. The first one is a stereotaxic transplantation of cells into the brain. Given, 
in PD, that brain damage principally occurs in both striatum (dopaminergic terminals) and 
SNc (neuronal soma), the best transplantation site, that would provide the most efficient and 
widest SC engraftment, is unknown. Nowadays, striatal administration of SCs is the most 
common approach for pre-clinical trials in PD (Blandini et al., 2010; Yasuhara et al., 2006; 
Zhu et al., 2009), although SC transplantation in mfb is also feasible (Gu et al., 2009). Gu and 
colleagues showed that double injection of NT-3 transfected NSC in mfb and ventral 
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tegmental area of parkinsonian rats generates new TH positive cells in these areas with 
relevant behavioral and functional recovery (Gu et al., 2009).  
Although the intracerebral route has provided a large panel of positive results in animal 
models and has allowed a better understanding of mechanisms underlying disease 
pathology, independently of the graft site, an outsized dilemma still resides in its invasive 
nature. To bypass this concern intravascular administration has also been undertaken. 
Intravenous administration of MSC after in 6-OHDA lesioned rats yields preservation of 
dopaminergic system and relevant behavioral improvements, although no transplanted SCs 
were observed in brain one month after injection (Wang et al., 2010). The intravenous 
administration route has obvious clinical advantages compared to intracerebral injection, yet 
evident efficient therapeutic benefits are fully dependent on the appropriate number of cells 
reaching the lesion sites. Concordantly, Wang et al have reported that the majority of SCs 
injected intravenously mostly dispersed in pulmonary tissue (Wang et al., 2010). This is in high 
contrast with the intracerebral route in which a large amount of cells are injected directly in or 
may easily migrate within the nearer lesion site. In 6-OHDA lesioned rats, the number of SCs 
still present at the site of injection, 4 weeks after transplantation, was proportional to the 
number of cells initially injected (Cova et al., 2010). Regardless of the delivery route adopted 
for transplantation, the biological mechanisms activated by SC graft rely both on cellular 
replacement and activation of the endogenous repair mechanisms coupled to neurorescue 
effects exerted on degenerating neurons (Lindvall and Kokaia, 2010). To date, no data from 
comparative studies between several administration routes (e.g., intrastriatal, intraventricular, 
and intravenous injections) of SC delivery in PD patients are available, although open labeled 
clinical trials with stereotaxic surgery have been already conducted (Venkataramana et al., 
2010). An interesting clinical approach by multiple administration routes for the treatment of 
spinal cord injuries has just been developed. Such strategy induces noteworthy with 
improvements of the life quality for patients (Geffner et al., 2008) and could be very positively 
applied to chronic degenerative diseases such as PD.  
Recently, an innovative alternative route for SC administration via a intranasal drop has 
been developed in an animal model of PD. MSC delivered into rat nostrils were found to 
migrate to lesion brain areas where they survived for at least 6 months (Danielyan et al., 
2011). In these animals striatal dopamine levels were increased and motor functions 
improved up to 68% of values observed in control animals (Danielyan et al., 2011). This 
administration route appears safe and could potentially be repeated overtime in a given 
patients. The intranasal procedure could avoid problems related to surgical implantation of 
SCs, although the positive outcomes need to be further confirmed before any clinical 
applications. 
Future therapeutic trials should also evaluate how the time point at which SC 
transplantation is performed, with respect to the cerebral insult, may influence efficacy of 
the procedure: earlier cell grafts may provide effective neuroprotection to degenerating 
neurons but the hostile environment may endanger their long-term survival by spreading 
disease hallmarks (Kordower et al., 2008; Li et al., 2008; Mendez et al., 2008). In principle, a 
time interval sufficient to allow in vitro expansion of autologous SCs, would obviously be 
desirable both from a practical and clinical perspective. On the other hand, transplantation 
at later disease stages, when cell loss is almost complete, will mainly aim at replacing lost 
dopaminergic neurons and will certainly be affected by the reduced expression of homing 
signals secreted in degenerative brain tissues. Conversely, transplantation at early stage will 
mostly rely on rescue and regeneration of surviving neurons. For CNS repair, 
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transplantation of proliferating progenitors cells, whose fate is less predictable since they are 
more proliferative than neurons, would face difficulties in sorting from stray pluripotent 
SCs, in the absence of specific markers. A clear trial design will necessarily need to take in 
account all these different biological mechanisms and, most importantly, will require the 
development of the appropriate biomarkers (Rascol, 2009) to follow disease progression.  
The choice of a specific SC type and its state of differentiation, as well as the amount of cells 
and route of administration will depend on the experimental endpoints, keeping in mind 
that each one faces inherent problems connected to local control of immune rejection, final 
differentiation towards dopaminergic neurons and cytokine release distally. For example 
transplantation of ES cells can lead to tumor formation and systemic injection of SCs may 
result in dispersion of the cells in non-target tissues. Circulating HSC could participate in 
the regeneration of peripheral tissues/organs, but only if a sufficient number of SCs is 
activated. Finally, as clearly pointed out by Irving Weissman, any future SC clinical 
application in neurodegenerative diseases will need to respect the four thresholds of clinical 
effectiveness: 1) cell homing to the diseased or injured tissue 2) effective engraftment, not 
just fusion with host cells 3) physiological effectiveness 4) permanence overtime (Weissman, 
2000). 
8. In vivo imaging and transplantation 
As mentioned above animal models of PD are fundamental tools to evaluate feasibility 
and potential of a given SC population.  To date translation of results obtained in pre-
clinical animal models of PD has been difficult. In particular, the effect and long-term 
survival of transplanted cells remains an open issue. The development of innovative 
imaging techniques, combined with the creation of reporter transgenic mice, has widen 
our understanding of some pathological mechanisms of the disease and allowed the 
identification of specific pharmacological targets (van Nuenen et al., 2009). Precise 
tracking of transplanted SCs through novel imaging techniques, as well as monitoring of 
engraftment efficiency directly in vivo allows the immediate correlation between beneficial 
effects and SC localization/amount (Lee et al., 2008). Genetic tags have and continue to 
help researchers and bioethicists to track transplanted cells overtime following their 
behavior and dispersion in tissues in animals. The simplest tag uses genetic 
recombination to introduce a fluorescent marker, such as green fluorescent protein, into a 
cell, but magnetic nanoparticles have also been proven to be helpful (Ferreira et al., 2008). 
Since cell therapy relies on SC involvement in physiological circuits their upshots could 
persist over a long time and should, therefore, be devoid of side effects. Homing, 
engraftment, cell fate, persistence and tumor formation of labeled SCs and their progeny 
needs to be carefully evaluated and could potentially be assessed using in vivo imaging. In 
complex neurodegenerative diseases, such as PD, grafted SCs or derived progenitor cells 
may protect residual neurons rather than replacing the degenerated ones. Therefore, 
tagged grafts could be easily characterized to determine if transplanted cells trigger 
endogenous mechanisms of repair or whether they directly replace lost cell populations. 
Successful application of magnetically-labeled mouse embryonic SCs to a rat model of PD 
coupled to the study of their diffusion up to 6 months post transplant has already 
demonstrated the feasibility and safety of this approach (Stroh et al., 2009). Imaging 
techniques are already used to study early and presymptomatic stages of PD (Wu et al., 
2011) and effectively measures outcomes in clinical trials of neuroprotection demonstrate 
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that  it is a practical non invasive method extensible to all PD patients (Pavese et al., 2009). 
PET measurements of 6-(18F) fluorodopa (18F-FDOPA) uptake indicate nigrostriatal 
neuronal integrity and may provide a useful endophenotype for PD linkage studies 
(Kumakura and Cumming, 2009). Clinical benefits and graft viability of embryonic 
dopamine cell implantation have been followed by functional imaging for up to 4 years 
after graft in 33 patients, thus correlating motor improvements with increased 18F-
FDOPA uptake (Ma et al., 2010).  
9. Conclusions 
Gaining more information about the pathology of the disease, the probable behavior of the 
grafted cells, as well as the reciprocal interconnections between the transplants and the host 
environment in animal models will be useful to predict possible complications and 
undesirable side effects readily translatable to future clinical trials for PD patients (Li et al., 
2010b). Caution needs to be adapted since xenograft models of disease in animals may not 
accurately predict the same response in humans due to inherent differences. However, pre-
clinical data will help improve patient selection for future clinical trials, assess restoration of 
brain connectivity, and monitor inflammatory processes in the continuous search of novel 
therapeutic targets (Politis and Piccini, 2010). Moreover, targeted delivery of SCs through 
alternative routes could be easily compared in animal models. Concordantly, one objective 
of modern neuroimaging is to identify markers for clinical diagnosis, monitor the disease 
progression, define the exact SC placement and analyze the impact of long-term drug/cell 
therapy through the direct spatio-temporal visualization of SCs as well as their effect on 
disease progression in patients, using non invasive techniques (Lee et al., 2008). A successful 
SC therapy requires extensive knowledge on SC properties, appropriate harvesting, 
manipulation and apt implantation, but also subsequent graft monitoring in the long time to 
verify the permanence of reparative mechanisms (Nikolic et al., 2009). On the basis of these 
data, it may be possible to properly select SC type, administration timing and delivery route 
for specific disease entities, anatomic areas, and physiologic circumstances to obtain 
reproducible experimental results for the creation of effective clinical protocols (Lindvall 
and Kokaia, 2010).  
Additionally, cell transplantation in animal is often performed before or contemporaneously 
to neurotoxin lesion. Further development of experimental models that more accurately 
recreate neurodegenerative conditions present in patients, in which treatment can only 
intervene when the degenerative process is overt and motor symptoms are manifest, is 
required. In particular, the creation of genetic animal models is becoming increasingly 
important to elucidate gene-environment interactions, define pathogenic mechanisms, and 
provide a platform for testing cell therapeutic interventions (Magen and Chesselet, 2010).  
The development and validation of conventional pharmacological therapy for clinical use is 
a long process that usually requires at least a decade. Cell transplantation, which represents 
an advanced therapeutic strategy far more complex than any pharmaceutical compound, 
was introduced surprisingly early into the clinic. Although some positive effects have been 
observed in the pioneering clinical studies sufficient caution should be taken before this 
strategy can be “routinely” applied to PD patients in order to avoid complications that may 
set back the field. In particular, defining and validating a specific cell type that may be 
consistently used in transplantation procedures is still a milestone that needs to be achieved. 
Extensive interactions and communication between clinicians and pre-clinical scientists is 
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mandatory to allow the constant fine-tuning of the design of therapeutic strategies for PD 
patients. 
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Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms,
pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed
primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic,
a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration
progresses despite the current therapies until the cell loss is so great that the quality of normal life is
compromised. The dopamine precursor levodopa is the most valuable drug currently available for the
treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around
five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the
mechanisms of degeneration and to develop disease modifying therapies.
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